Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase ii, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
- Resource Type
- Article
- Source
- In
Clinical Therapeutics 2007 29(4):626-639 - Subject
- Language
- ISSN
- 0149-2918